Since the legalization of medical cannabis in 2018, Malta has been leveraging its renowned pharmaceutical regulatory framework to position itself as a leader in the field.
Activities related to the production of cannabis for medicinal and research purposes are regulated by the Malta Medicines Authority through comprehensive evaluation of scientific and technical documentation, security considerations, and EU Good Manufacturing Practice (GMP).
Alphafarma Operations Ltd., Salus Europe’s production facility in Malta has undergone such a thorough review process, leading to the attainment of EU-GMP certification, ensuring that all products are consistently formulated and processed to the highest standards of quality, safety and efficacy.
First Growth passed a successful round of audits and inspections, conducted by SAPHRA, in order to receive its license to cultivate medical cannabis in February 2021. Since then, First Growth has been working with the rest of the Salus Europe team to develop SOP’s, plan and procure the necessary final processing equipment and prepare for initial strain selection and test harvests.